GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Net Income (Continuing Operations)

GENinCode (LSE:GENI) Net Income (Continuing Operations) : £-4.43 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. GENinCode's Net Income (Continuing Operations) for the six months ended in Dec. 2024 was £-2.01 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was £-4.43 Mil.


GENinCode Net Income (Continuing Operations) Historical Data

The historical data trend for GENinCode's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Net Income (Continuing Operations) Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
Get a 7-Day Free Trial -1.17 -4.14 -5.56 -7.02 -4.43

GENinCode Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -3.23 -3.50 -3.52 -2.43 -2.01

GENinCode Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-4.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GENinCode  (LSE:GENI) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


GENinCode Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of GENinCode's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


GENinCode Business Description

Traded in Other Exchanges
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.